Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Analyst desks were busy on Monday, with notable moves across financials, technology, and healthcare.
The biggest banking call was a downgrade of TFC. Truist Financial was cut from Hold to Sell, with the consensus target sitting at $55.32. The stock carries a market cap of $63.5 billion. The move comes as regional banks face pressure from credit costs and a shifting rate outlook.
On the tech side, MRVL saw its average analyst target price lifted to $252.26 from $249.33. The $214 billion chip designer has benefited from AI infrastructure spending. CRWD also got a target bump, now averaging $181.53 versus $179.69 prior.
In healthcare, BIIB received a target price increase, with consensus moving to $222.0. Biogen's $31.9 billion market cap reflects ongoing hopes around its neuroscience pipeline. saw a recommendation removed, trimming coverage to 32 analysts.
Energy giant XOM picked up a fresh new recommendation with a consensus target of $169.48, adding to its 21-analyst coverage. SLB faced a slight target trim, with consensus slipping to $61.79.
MSFT also saw a marginal target cut to $560.21, though overall sentiment remains strongly positive with 53 buy-equivalent ratings.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
